A multicenter prospective study to define the natural history of BK viral infections in kidney transplantation.
BK polyomavirus
BKV
BKV-associated nephropathy
BKVN
kindney
transplant recipients
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
11 Feb 2024
11 Feb 2024
Historique:
received:
15
12
2023
accepted:
19
12
2023
medline:
11
2
2024
pubmed:
11
2
2024
entrez:
11
2
2024
Statut:
aheadofprint
Résumé
BK polyomavirus (BKV) can cause permanent loss of allograft function due to BKV-associated nephropathy (BKVN) in kidney transplant recipients. Besides immunosuppression reduction, there are no consistently effective interventions for BKV infection. Study purpose was to define natural history of BKV infection, identify risk factors for BKV reactivation and BKVN in kidney transplant recipients, and inform the design/conduct of future clinical trials of BKV-targeted therapeutics. We conducted a multicenter prospective observational study of incident kidney transplant recipients at six U.S. transplant centers. Participants were monitored every 4 weeks for BKV reactivation and followed for up to 24 months post-transplant. We used regression models (logistic, survival, mixed models) to study relationships between BK viremia/BKVN, clinical characteristics, and allograft function. We enrolled 335 participants. Fifty-eight (17%) developed BK viremia, 6 (2%) developed biopsy-proven BKVN, and 29 (9%) developed suspected/presumed BKVN (defined as BKV viral load > 10,000 copies/mL without biopsy). Male donor sex was associated with lower odds for BK viremia, whereas recipient Black race was associated with two-fold increased odds for BK viremia. Recipient female sex was associated with more rapid clearance of BK viremia. Persistent BK viremia/BKVN was associated with poorer allograft function by 24 months post-transplant. We identified multiple donor and recipient demographic factors associated with risk for BKV infection and poorer allograft function by 24 months post-transplant. This may help design future clinical trials of therapies to prevent or mitigate the deleterious impact of BKV reactivation on kidney transplant outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
BK polyomavirus (BKV) can cause permanent loss of allograft function due to BKV-associated nephropathy (BKVN) in kidney transplant recipients. Besides immunosuppression reduction, there are no consistently effective interventions for BKV infection. Study purpose was to define natural history of BKV infection, identify risk factors for BKV reactivation and BKVN in kidney transplant recipients, and inform the design/conduct of future clinical trials of BKV-targeted therapeutics.
METHODS
METHODS
We conducted a multicenter prospective observational study of incident kidney transplant recipients at six U.S. transplant centers. Participants were monitored every 4 weeks for BKV reactivation and followed for up to 24 months post-transplant. We used regression models (logistic, survival, mixed models) to study relationships between BK viremia/BKVN, clinical characteristics, and allograft function.
RESULTS
RESULTS
We enrolled 335 participants. Fifty-eight (17%) developed BK viremia, 6 (2%) developed biopsy-proven BKVN, and 29 (9%) developed suspected/presumed BKVN (defined as BKV viral load > 10,000 copies/mL without biopsy). Male donor sex was associated with lower odds for BK viremia, whereas recipient Black race was associated with two-fold increased odds for BK viremia. Recipient female sex was associated with more rapid clearance of BK viremia. Persistent BK viremia/BKVN was associated with poorer allograft function by 24 months post-transplant.
CONCLUSIONS
CONCLUSIONS
We identified multiple donor and recipient demographic factors associated with risk for BKV infection and poorer allograft function by 24 months post-transplant. This may help design future clinical trials of therapies to prevent or mitigate the deleterious impact of BKV reactivation on kidney transplant outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14237Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201100036C
Pays : United States
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Qeska D, Wong RBK, Famure O, et al. Incidence, risk factors, outcomes, and clinical management of BK viremia in the modern era of kidney transplantation. Transpl Infect Dis. 2022;24(6):e13915.
Hirsch HH, Randhawa PS, Practice AIDCo. BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13528.
Seifert ME, Gunasekaran M, Horwedel TA, et al. Polyomavirus reactivation and immune responses to kidney-specific self-antigens in transplantation. J Am Soc Nephrol. 2017;28(4):1314-1325.
Hirsch HH, Randhawa P. BK virus in solid organ transplant recipients. Am J Transpl. 2009;9(Suppl 4):S136-S146.
Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol. 2007;2(Suppl 1):S36-S46.
Smith JM, Dharnidharka VR, Talley L, Martz K, McDonald RA. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol. 2007;2(5):1037-1042.
Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005;5(3):582-594.
Randhawa P, Ho A, Shapiro R, et al. Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol. 2004;42(3):1176-1180.
Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488-496.
Nickeleit V, Singh HK, Randhawa P, et al. The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J Am Soc Nephrol. 2018;29(2):680-693.
Imlay H, Baum P, Brennan DC, et al. Consensus definitions of BK polyomavirus nephropathy in renal transplant recipients for clinical trials. Clin Infect Dis. 2022;75(7):1210-1216.
Breyer I, Dodin B, Djamali A, et al. Risk factors and outcomes of BK viremia among deceased donor kidney transplant recipients based on donor characteristics. Transpl Infect Dis. 2022;24(1):e13768.
Lee S, Lee KW, Kim SJ, Park JB. Clinical characteristic and outcomes of BK virus infection in kidney transplant recipients managed using a systematic surveillance and treatment strategy. Transplant Proc. 2020;52(6):1749-1756.
Thangaraju S, Gill J, Wright A, Dong J, Rose C, Gill J. Risk factors for BK polyoma virus treatment and association of treatment with kidney transplant failure: insights from a paired kidney analysis. Transplantation. 2016;100(4):854-861.
Hirsch HH, Randhawa P. BK polyomavirus in solid organ transplantation. Am J Transpl. 2013;(13 Suppl 4):179-188.
Sood P, Senanayake S, Sujeet K, et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. Transplantation. 2012;94(8):814-821.
Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation. 2008;85(6):850-854.
Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transpl. 2010;10(12):2615-2623.
Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transpl. 2007;7(12):2727-2735.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transpl. 2010;10(2):407-415.
Hricik D, Armstrong B, Alhamad T, et al. Infliximab induction lacks efficacy and increases BK virus infection in deceased donor kidney transplant recipients. J Am Soc Nephrol. 2022;34(1):145-159.
Sawinski D, Forde KA, Trofe-Clark J, et al. Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies. J Am Soc Nephrol. 2015;26(4):966-975.
Kling CL, Wright AT, Katz SE, et al. Dynamics of urinary polyomavirus shedding in healthy adult women. J Med Virol. 2012;84(9):1459-1463.
Moens U, Van Ghelue M, Johansen B, Seternes OM. Concerted expression of BK virus large T- and small t-antigens strongly enhances oestrogen receptor-mediated transcription. J Gen Virol. 1999;80(Pt 3):585-594.
Maliakkal JG, Brennan DC, Goss C, et al. Ureteral stent placement and immediate graft function are associated with increased risk of BK viremia in the first year after kidney transplantation. Transpl Int. 2017;30(2):153-161.
Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909-1919.
Crowson CN, Reed RD, Shelton BA, MacLennan PA, Locke JE. Lymphocyte-depleting induction therapy lowers the risk of acute rejection in African-American pediatric kidney transplant recipients. Pediatr Transplant. 2017;21(1).
Yanik MV, Seifert ME, Locke JE, et al. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients. Pediatr Transplant. 2019;23(5):e13494.
David-Neto E, Agena F, Silva Ribeiro David D, et al. Effect of polyoma viremia on 3-year allograft kidney function. Transpl Infect Dis. 2019;21(2):e13056.
Hundemer GL, White CA, Norman PA, et al. Performance of the 2021 race-free CKD-EPI creatinine- and cystatin c-based estimated GFR equations among kidney transplant recipients. Am J Kidney Dis. 2022;80(4):462-472.e1.
Gutiérrez OM, Sang Y, Grams ME, et al. Association of estimated GFR calculated using race-free equations with kidney failure and mortality by Black vs. Non-Black race. JAMA. 2022;327(23):2306-2316.
Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79(2):268-288.e1.
Seifert ME, Agarwal G, Bernard M, et al. Impact of subclinical borderline inflammation on kidney transplant outcomes. Transplant Direct. 2021;7(2):e663.